Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

Thong KY, Jose B, Sukumar N, Cull ML, Mills AP, Sathyapalan T, Shafiq W, Rigby AS, Walton C, Ryder RE

Diabetes, obesity & metabolism1 Aug 2011Cited by 56 (Europe PMC)

PMID21410858DOI10.1111/j.1463-1326.2011.01393.xPepBankPUB-21410858

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In the exenatide audit, continued insulin use was linked to a smaller HbA1c decrease than treatment without insulin.
In plain wordsIn exenatide users, continued insulin use was linked to less HbA1c reduction than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c change
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
0.51%
exenatide with insulin
HbA1c reduction
0.94%
exenatide without insulin
Source sentences
Summary
Comparing patients who continued insulin with exenatide with non-insulin-treated patients, mean (±s.e.) latest HbA1c and weight reduction (median 26 weeks) were 0.51 ± 0.06 versus 0.94 ± 0.04% (p < 0.001) and 5.8 ± 0.2 versus 5.5 ± 0.1 kg (p = 0.278).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085801
02HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In the exenatide audit, weight reduction did not differ significantly between continued insulin and non-insulin groups.
In plain wordsIn exenatide users, weight reduction did not differ significantly between continued insulin and treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight reduction
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
5.8 kg
exenatide with insulin
Weight reduction
5.5 kg
exenatide without insulin
Source sentences
Summary
Comparing patients who continued insulin with exenatide with non-insulin-treated patients, mean (±s.e.) latest HbA1c and weight reduction (median 26 weeks) were 0.51 ± 0.06 versus 0.94 ± 0.04% (p < 0.001) and 5.8 ± 0.2 versus 5.5 ± 0.1 kg (p = 0.278).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085802
03HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome
In the exenatide audit, insulin-treated patients had more exenatide discontinuation than non-insulin-treated patients.
In plain wordsIn exenatide users, insulin treatment was linked to more exenatide discontinuation than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseExenatide discontinuation
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Adverse events · Metabolic and weight
Measurements
Discontinuation
31%
with insulin
Discontinuation
13.9%
without insulin
Source sentences
Summary
Insulin-treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085803
04HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome
In the exenatide audit, insulin-treated patients had more hypoglycaemia than non-insulin-treated patients.
In plain wordsIn exenatide users, insulin treatment was linked to more low blood sugar than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHypoglycaemia
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Adverse events · Metabolic and weight
Measurements
Hypoglycaemia
8.9%
with insulin
Hypoglycaemia
6.1%
without insulin
Source sentences
Summary
Insulin-treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085804
05HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome
In the exenatide audit, insulin-treated patients had more gastrointestinal side effects than non-insulin-treated patients.
In plain wordsIn exenatide users, insulin treatment was linked to more gut side effects than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGastrointestinal side effects
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Gastrointestinal side effects
28.4%
with insulin
Gastrointestinal side effects
25%
without insulin
Source sentences
Summary
Insulin-treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085805
06HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In the exenatide audit, insulin-treated patients had more treatment dissatisfaction than non-insulin-treated patients.
In plain wordsIn exenatide users, insulin treatment was linked to more treatment dissatisfaction than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment dissatisfaction
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Quality of life · Metabolic and weight
Measurements
Dissatisfaction
20.8%
with insulin
Dissatisfaction
5.7%
without insulin
Source sentences
Summary
Insulin-treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085806
07HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In exenatide users continuing insulin, 34.2% achieved an HbA1c reduction ≥1%.
In plain wordsIn exenatide users continuing insulin, 34.2% achieved an HbA1c reduction ≥1%.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c reduction ≥1%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Responders
34.2%
continuing insulin
Source sentences
Summary
However, 34.2% of the patients continuing insulin still achieved HbA1c reduction ≥1%.
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085807
08HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In the exenatide audit, insulin-treated patients had greater sulphonylurea discontinuation than non-insulin-treated patients.
In plain wordsIn exenatide users, insulin treatment was linked to more sulphonylurea discontinuation than treatment without insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSulphonylurea discontinuation
Study
n: not reported in source
Comparator
Non-insulin-treated exenatide patients
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was significant insulin discontinuation, dose reduction and greater sulphonylurea discontinuation among insulin-treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The Association of British Clinical Diabetologists hosted a password-protected, online collection of anonymized data of exenatide use in real clinical practice.
Summary · context
HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non-insulin and insulin-treated patients.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2141085810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.